No price history available.
Key financial summary
Financials in RUB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | RUBm | 19,133 | 25,220 | 25,222 | 27,631 | 33,122 | N/A | N/A | N/A |
| Operating profit | RUBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | RUBm | 4,196 | 6,003 | 4,560 | 7,630 | 9,931 | N/A | N/A | N/A |
| EPS reported | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | RUBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | RUBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | RUBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | RUB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in RUB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
MD Medical Group Investments Plc operates as an investment holding company, delivering comprehensive medical services primarily to women and children throughout Russia. Its extensive service portfolio encompasses maternal and gynecological health, fertility treatments including in-vitro fertilization (IVF), and pediatric care. Additionally, the company provides a wide array of specialized services such as diagnostics, urology, radiology, surgical interventions, traumatology, rehabilitation, cardiology, oncology, endovascular procedures, and various laboratory examinations. The group also engages in pharmaceutical retailing and offers support services. As of March 28, 2022, it managed a network of 47 healthcare facilities, consisting of 8 hospitals and 39 outpatient clinics, spread across 27 cities and 25 distinct regions. Founded in 2006, the company is headquartered in Nicosia, Cyprus, and operates as a subsidiary of MD Medical Holding Limited.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
MD Medical Group Investments Plc (MDMG.ME)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
MD Medical Group Investments Plc operates as an investment holding company, delivering comprehensive medical services primarily to women and children throughout Russia. Its extensive service portfolio encompasses maternal and gynecological health, fertility treatments including in-vitro fertilization (IVF), and pediatric care. Additionally, the company provides a wide array of specialized services such as diagnostics, urology, radiology, surgical interventions, traumatology, rehabilitation, cardiology, oncology, endovascular procedures, and various laboratory examinations. The group also engages in pharmaceutical retailing and offers support services. As of March 28, 2022, it managed a network of 47 healthcare facilities, consisting of 8 hospitals and 39 outpatient clinics, spread across 27 cities and 25 distinct regions. Founded in 2006, the company is headquartered in Nicosia, Cyprus, and operates as a subsidiary of MD Medical Holding Limited.